基于免疫信息学的肠病毒D68免疫增强和非致敏性多表位亚基疫苗设计

IF 3.3 4区 医学 Q2 GENETICS & HEREDITY
Muhammad Suleman, Safir Ullah Khan, Hina Jabeen, Osama A Madkhali, Mohammed Ali Bakkari, Abdullah Alsalhi, Hadi M Yassine, Sergio Crovella
{"title":"基于免疫信息学的肠病毒D68免疫增强和非致敏性多表位亚基疫苗设计","authors":"Muhammad Suleman, Safir Ullah Khan, Hina Jabeen, Osama A Madkhali, Mohammed Ali Bakkari, Abdullah Alsalhi, Hadi M Yassine, Sergio Crovella","doi":"10.2174/0115665232336511250626200218","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Enterovirus D68 (EV-D68) is a non-enveloped, positive-sense, singlestranded RNA virus known for causing severe respiratory illnesses and its association with acute flaccid myelitis (AFM) in children. Despite its increasing public health significance, no vaccines or antiviral drugs are currently available for EV-D68. This study aimed to design an immune-boosting multi-epitope subunit vaccine against EV-D68 using advanced immunoinformatic and machine learning approaches.</p><p><strong>Methods: </strong>Capsid proteins VP1, VP2, and VP3 of EV-D68 were screened for immunogenic HTL, CTL, and B-cell epitopes to develop a non-allergenic, highly immunogenic multi-epitope vaccine. Predicted epitopes were subjected to 3D structural modeling and molecular dynamics simulations to validate folding and structural stability. Molecular docking and immune simulation techniques were employed to evaluate vaccine-TLR3 interactions and predict immune responses, respectively.</p><p><strong>Results: </strong>Molecular docking analysis revealed strong binding affinities between the vaccine constructs and the TLR3 receptor, with scores of -299 kcal/mol, -361 kcal/mol, -258 kcal/mol, and -312 kcal/mol for VP1, VP2, VP3, and combined vaccine-TLR3 complexes. Molecular dynamic simulation and dissociation constant analyses confirmed the strength of these interactions, with binding free energies ranging from -57.75 kcal/mol to -101.35 kcal/mol. Codon adaptation index (CAI) values of 0.96 and GC content of ~69% supported the high expression potential of the vaccine constructs. Immune simulations demonstrated robust immune responses characterized by elevated IgG, IgM, cytokines, and interleukins, along with effective antigen clearance.</p><p><strong>Discussion: </strong>The strong molecular interactions with TLR3 and simulated immune responses suggest that the designed vaccines can activate both innate and adaptive immunity. The high CAI and GC values support their expression feasibility in <i>E. coli</i>, enhancing prospects for production.</p><p><strong>Conclusion: </strong>This study provides a strong foundation for the development of a safe and effective EV-D68 vaccine, showcasing the potential of computational vaccine design.</p>","PeriodicalId":10798,"journal":{"name":"Current gene therapy","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Immunoinformatic Based Designing of Immune Boosting and Nonallergenic Multi-epitope Subunit Vaccine Against the Enterovirus D68.\",\"authors\":\"Muhammad Suleman, Safir Ullah Khan, Hina Jabeen, Osama A Madkhali, Mohammed Ali Bakkari, Abdullah Alsalhi, Hadi M Yassine, Sergio Crovella\",\"doi\":\"10.2174/0115665232336511250626200218\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Enterovirus D68 (EV-D68) is a non-enveloped, positive-sense, singlestranded RNA virus known for causing severe respiratory illnesses and its association with acute flaccid myelitis (AFM) in children. Despite its increasing public health significance, no vaccines or antiviral drugs are currently available for EV-D68. This study aimed to design an immune-boosting multi-epitope subunit vaccine against EV-D68 using advanced immunoinformatic and machine learning approaches.</p><p><strong>Methods: </strong>Capsid proteins VP1, VP2, and VP3 of EV-D68 were screened for immunogenic HTL, CTL, and B-cell epitopes to develop a non-allergenic, highly immunogenic multi-epitope vaccine. Predicted epitopes were subjected to 3D structural modeling and molecular dynamics simulations to validate folding and structural stability. Molecular docking and immune simulation techniques were employed to evaluate vaccine-TLR3 interactions and predict immune responses, respectively.</p><p><strong>Results: </strong>Molecular docking analysis revealed strong binding affinities between the vaccine constructs and the TLR3 receptor, with scores of -299 kcal/mol, -361 kcal/mol, -258 kcal/mol, and -312 kcal/mol for VP1, VP2, VP3, and combined vaccine-TLR3 complexes. Molecular dynamic simulation and dissociation constant analyses confirmed the strength of these interactions, with binding free energies ranging from -57.75 kcal/mol to -101.35 kcal/mol. Codon adaptation index (CAI) values of 0.96 and GC content of ~69% supported the high expression potential of the vaccine constructs. Immune simulations demonstrated robust immune responses characterized by elevated IgG, IgM, cytokines, and interleukins, along with effective antigen clearance.</p><p><strong>Discussion: </strong>The strong molecular interactions with TLR3 and simulated immune responses suggest that the designed vaccines can activate both innate and adaptive immunity. The high CAI and GC values support their expression feasibility in <i>E. coli</i>, enhancing prospects for production.</p><p><strong>Conclusion: </strong>This study provides a strong foundation for the development of a safe and effective EV-D68 vaccine, showcasing the potential of computational vaccine design.</p>\",\"PeriodicalId\":10798,\"journal\":{\"name\":\"Current gene therapy\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-07-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current gene therapy\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0115665232336511250626200218\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"GENETICS & HEREDITY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current gene therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115665232336511250626200218","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0

摘要

肠病毒D68 (EV-D68)是一种非包膜、阳性意义的单链RNA病毒,已知可引起严重呼吸道疾病,并与儿童急性弛缓性脊髓炎(AFM)有关。尽管EV-D68具有越来越重要的公共卫生意义,但目前尚无针对EV-D68的疫苗或抗病毒药物。本研究旨在利用先进的免疫信息学和机器学习方法设计一种针对EV-D68的免疫增强多表位亚基疫苗。方法:筛选EV-D68衣壳蛋白VP1、VP2和VP3的免疫原性HTL、CTL和b细胞表位,制备非致敏性、高免疫原性的多表位疫苗。预测的表位进行了三维结构建模和分子动力学模拟,以验证折叠和结构稳定性。分子对接和免疫模拟技术分别用于评估疫苗- tlr3相互作用和预测免疫应答。结果:分子对接分析显示,疫苗构建体与TLR3受体之间具有较强的结合亲和力,VP1、VP2、VP3和疫苗-TLR3联合复合物的结合得分分别为-299、-361、-258和-312 kcal/mol。分子动力学模拟和解离常数分析证实了这些相互作用的强度,结合自由能在-57.75 kcal/mol到-101.35 kcal/mol之间。密码子适应指数(CAI)为0.96,GC含量为~69%,表明该疫苗构建体具有较高的表达潜力。免疫模拟显示了强大的免疫反应,其特征是IgG、IgM、细胞因子和白细胞介素升高,以及有效的抗原清除。讨论:与TLR3的强分子相互作用和模拟免疫反应表明,设计的疫苗可以激活先天免疫和适应性免疫。高CAI和GC值支持其在大肠杆菌中的表达可行性,提高了生产前景。结论:本研究为开发安全有效的EV-D68疫苗提供了坚实的基础,展示了计算疫苗设计的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Immunoinformatic Based Designing of Immune Boosting and Nonallergenic Multi-epitope Subunit Vaccine Against the Enterovirus D68.

Introduction: Enterovirus D68 (EV-D68) is a non-enveloped, positive-sense, singlestranded RNA virus known for causing severe respiratory illnesses and its association with acute flaccid myelitis (AFM) in children. Despite its increasing public health significance, no vaccines or antiviral drugs are currently available for EV-D68. This study aimed to design an immune-boosting multi-epitope subunit vaccine against EV-D68 using advanced immunoinformatic and machine learning approaches.

Methods: Capsid proteins VP1, VP2, and VP3 of EV-D68 were screened for immunogenic HTL, CTL, and B-cell epitopes to develop a non-allergenic, highly immunogenic multi-epitope vaccine. Predicted epitopes were subjected to 3D structural modeling and molecular dynamics simulations to validate folding and structural stability. Molecular docking and immune simulation techniques were employed to evaluate vaccine-TLR3 interactions and predict immune responses, respectively.

Results: Molecular docking analysis revealed strong binding affinities between the vaccine constructs and the TLR3 receptor, with scores of -299 kcal/mol, -361 kcal/mol, -258 kcal/mol, and -312 kcal/mol for VP1, VP2, VP3, and combined vaccine-TLR3 complexes. Molecular dynamic simulation and dissociation constant analyses confirmed the strength of these interactions, with binding free energies ranging from -57.75 kcal/mol to -101.35 kcal/mol. Codon adaptation index (CAI) values of 0.96 and GC content of ~69% supported the high expression potential of the vaccine constructs. Immune simulations demonstrated robust immune responses characterized by elevated IgG, IgM, cytokines, and interleukins, along with effective antigen clearance.

Discussion: The strong molecular interactions with TLR3 and simulated immune responses suggest that the designed vaccines can activate both innate and adaptive immunity. The high CAI and GC values support their expression feasibility in E. coli, enhancing prospects for production.

Conclusion: This study provides a strong foundation for the development of a safe and effective EV-D68 vaccine, showcasing the potential of computational vaccine design.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current gene therapy
Current gene therapy 医学-遗传学
CiteScore
6.70
自引率
2.80%
发文量
46
期刊介绍: Current Gene Therapy is a bi-monthly peer-reviewed journal aimed at academic and industrial scientists with an interest in major topics concerning basic research and clinical applications of gene and cell therapy of diseases. Cell therapy manuscripts can also include application in diseases when cells have been genetically modified. Current Gene Therapy publishes full-length/mini reviews and original research on the latest developments in gene transfer and gene expression analysis, vector development, cellular genetic engineering, animal models and human clinical applications of gene and cell therapy for the treatment of diseases. Current Gene Therapy publishes reviews and original research containing experimental data on gene and cell therapy. The journal also includes manuscripts on technological advances, ethical and regulatory considerations of gene and cell therapy. Reviews should provide the reader with a comprehensive assessment of any area of experimental biology applied to molecular medicine that is not only of significance within a particular field of gene therapy and cell therapy but also of interest to investigators in other fields. Authors are encouraged to provide their own assessment and vision for future advances. Reviews are also welcome on late breaking discoveries on which substantial literature has not yet been amassed. Such reviews provide a forum for sharply focused topics of recent experimental investigations in gene therapy primarily to make these results accessible to both clinical and basic researchers. Manuscripts containing experimental data should be original data, not previously published.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信